In this study the authors address the efficacy and safety of Gamma Knife surgery (GKS) in patients with adrenocorticotropic hormone–secreting pituitary adenomas.
A review of data collected from a prospective GKS database between January 1990 and March 2005 was performed in patients with Cushing's disease. All but one patient underwent resection for a pituitary tumor, without achieving remission. Successful endocrine outcome after GKS was defined as a normal 24-hour urinary free cortisol (UFC) concentration posttreatment after a minimum of 1 year of follow up. Patient records were also evaluated for changes in tumor volume, development of new hormone deficiencies, visual acuity, cranial nerve neuropathies, and radiation-induced imaging changes. Ninety evaluable patients had undergone GKS, with a mean endocrine follow-up duration of 45 months (range 12–132 months). The mean dose to the tumor margin was 23 Gy (median 25 Gy).
Normal 24-hour UFC levels were achieved in 49 patients (54%), with an average time of 13 months after treatment (range 2–67 months). In the 49 patients in whom a tumor was visible on the planning magnetic resonance (MR) image, a decrease in tumor size occurred in 39 (80%), in seven patients there was no change in size, and tumor growth occurred in three patients. Ten patients (20%) experienced a relapse of Cushing's disease after initial remission; the mean time to recurrence was 27 months (range 6–60 months). Seven of these patients underwent repeated GKS, with three patients achieving a second remission. New hormone deficiencies developed in 20 patients (22%), with hypothyroidism being the most common endocrinopathy after GKS. Five patients experienced new visual deficits or third, fourth, or sixth cranial nerve deficits; two of these patients had undergone prior conventional fractionated radiation therapy, and four of them had received previous GKS. Radiation-induced changes were observed on MR images in three patients; one had symptoms attributable to these changes.
Gamma Knife surgery is an effective treatment for persistent Cushing's disease. Adenomas with cavernous sinus invasion that are not amenable to resection are treatable with the Gamma Knife. A second GKS treatment appears to increase the risk of cranial nerve damage. These results demonstrate the value of combining two neurosurgical treatment modalities—microsurgical resection and GKS—in the management of pituitary adenomas.
Abbreviations used in this paper:ACTH = adrenocorticotropic hormone; CT = computed tomography; GKS = Gamma Knife surgery; MR = magnetic resonance; UFC = urinary free cortisol.
Address reprint requests to: Jason P. Sheehan, M.D., Ph.D., Department of Neurological Surgery, University of Virginia Health System, P.O. Box 800212, Charlottesville, Virginia 22908-00212. email:
ArnottRDPestellRGMcKelviePAHendersonJKMcNeillPMAlfordFP: A critical evaluation of transsphenoidal pituitary surgery for the treatment of Cushing's disease: prediction of outcome. Acta Endocrinol123:423–4301990
ArnottRD, PestellRG, McKelviePA, HendersonJK, McNeillPM, AlfordFP: A critical evaluation of transsphenoidal pituitary surgery for the treatment of Cushing's disease: prediction of outcome. 123:423–430, 1990)| false
DoppmanJLNiemanLKChangRYanovskiJCutlerGBJrChrousosGP: Selective venous sampling from the cavernous sinuses is not a more reliable technique than sampling from the inferior petrosal sinuses in Cushing's syndrome. J Clin Endocrinol Metab80:2485–24891995
DoppmanJL, NiemanLK, ChangR, YanovskiJ, CutlerGBJr, ChrousosGP, : Selective venous sampling from the cavernous sinuses is not a more reliable technique than sampling from the inferior petrosal sinuses in Cushing's syndrome. 80:2485–2489, 1995)| false
EstradaJGarcia-UriaJLamasCAlfaroJLucasTDiezS: The complete normalization of the adrenocortical function as the criterion of cure after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab86:5695–56992001
EstradaJ, Garcia-UriaJ, LamasC, AlfaroJ, LucasT, DiezS, : The complete normalization of the adrenocortical function as the criterion of cure after transsphenoidal surgery for Cushing's disease. 86:5695–5699, 2001)| false
HoybyeCGrenbackERahnTDegerbladMThorenMHultingAL: Adrenocortcotrophic hormone-producing pituitary tumors: 12- to 22-year follow-up after treatment with stereotactic radiosurgery. Neurosurgery49:284–2922001
HoybyeC, GrenbackE, RahnT, DegerbladM, ThorenM, HultingAL: Adrenocortcotrophic hormone-producing pituitary tumors: 12- to 22-year follow-up after treatment with stereotactic radiosurgery. 49:284–292, 2001)| false
PollockBENippoldtTBStaffordSLFooteRLAbboudCF: Results of stereotactic radiosurgery in patients with hormone-producing pituitary adenomas: factors associated with endocrine normalization. J Neurosurg97:525–5302002
PollockBE, NippoldtTB, StaffordSL, FooteRL, AbboudCF: Results of stereotactic radiosurgery in patients with hormone-producing pituitary adenomas: factors associated with endocrine normalization. 97:525–530, 2002)| false
RahnTThorenMWernerSStereotactic radiosurgery in pituitary adenomas. FagliaGBeck-PeccozPAmbrosiBTravagliniPSpadaA: Pituitary Adenomas: New Trends in Basic and Clinical ResearchNew YorkExcerpta Medica1991. 303–312
RahnT, ThorenM, WernerS, Stereotactic radiosurgery in pituitary adenomas. FagliaG, Beck-PeccozP, AmbrosiB, TravagliniP, SpadaA: New York, Excerpta Medica, 1991. 303–312)| false